Ensifentrine 3 mg

DRUG2 trials

Sponsors

Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA, Verona Pharma plc

Conditions

Chronic Obstructive Pulmonary Disease

Phase 2

Clinical Study of Ensifentrine-Glycopyrrolate (MK-5884A/RPL554) Fixed-dose Combination Dose Ranging in Participants With COPD (MK-5884A-029/RPL554-CO-212)

CompletedNCT07016412

Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USAChronic Obstructive Pulmonary Disease

Start: 2025-07-31End: 2026-08-17Updated: 2026-09-11

A Phase II Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Single Inhaled Doses of Ensifentrine-glycopyrrolate Fixed Dose Combination, Ensifentrine, and Glycopyrrolate in Subjects With Chronic Obstructive Pulmonary Disease

CompletedNCT07132983

Verona Pharma plcChronic Obstructive Pulmonary Disease

Start: 2025-10-06End: 2025-11-28Updated: 2026-01-08